Biotech News
Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights
U.S. launch of ISEMBYLD™ (apitegromab-mstn), the first and only muscle-targeted therapy for children and adults living with spinal muscular atrophy (SMA), underway following September 11, 2026 FDA approval ISEMBYLD shipped to specialty network prior to quarter-end, reflecting Q3 2026 ISEMBYLD
